

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/415</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/22296</b> <b>(43) International Publication Date:</b> 23 December 1992 (23.12.92)
<b>(21) International Application Number:</b> PCT/FI92/00191 <b>(22) International Filing Date:</b> 18 June 1992 (18.06.92) <b>(30) Priority data:</b> 9113077.3 18 June 1991 (18.06.91) GB <b>(71) Applicant (for all designated States except US):</b> ORION-YHTYMÄ OY [FI/FI]; Orionintie 1, SF-02100 Espoo (FI). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PERTOVAARA, Antti [FI/FI]; Otsolahdentie 16 A 6, SF-02110 Espoo (FI). LINNANKOSKI, Ilkka [FI/FI]; Maununnenvantie 52 B, SF-00430 Helsinki (FI). VIRTANEN, Raimo [FI/FI]; Knaapintie 5, SF-21290 Rusko (FI).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), BG, CA, CH (European patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), NO, PL, RO, RU, SE (European patent), US.  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> USE OF ATIPAMEZOLE FOR THE TREATMENT OF MALE SEXUAL IMPOTENCE  <b>(57) Abstract</b>  This invention concerns the use of atipamezole or a pharmaceutically acceptable acid addition salt thereof for the treatment of male sexual impotence.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

USE OF ATIPAMEZOLE FOR THE TREATMENT  
OF MALE SEXUAL IMPOTENCE

This invention relates to a novel therapeutic treatment of male sexual  
5 impotence by the administration of atipamezole which is the INN-approved  
generic name for 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole or a  
pharmaceutically acceptable acid addition salt thereof.

Male impotence is a sexual dysfunction relating to difficulties in achieving  
and/or maintaining of sufficient penile erection. It can result from a variety of  
10 underlying causes ranging from purely psychogenic to completely physical  
dysfunctioning. Both surgical and pharmacological therapy have been used in  
the treatment of impotence. Surgical therapy (implantation of a penile prosthetic  
device) has been used successfully mainly in the case of a purely organic  
disease. A variety of agents have been suggested for the use as drug therapy in  
15 impotence but the reports of their effectiveness are mainly anecdotal in nature.  
The use of pharmacological therapy in impotence has thus not gained any wide  
acceptance so far.

A substantial amount of work has been devoted to identifying the  
neurotransmitters involved in the facilitation and inhibition of male sexual  
20 behaviour (see e.g. Bitran and Hull 1987, Neuroscience and Behavioral reviews  
11, 365-389). Noradrenergic neuro-transmission seems to have an important  
role.

Atipamezole is a selective and potent  $\alpha_2$ -adrenoceptor antagonist which  
is currently marketed for the reversal of sedative-analgesic veterinary drugs.  
25 Atipamezole has been disclosed e.g. in the European Patent EP 183492 as  
useful for the reversal of detomidine.

We have now found that this compound is also very effective in  
increasing male sexual capacity in a monkey model. These findings suggest  
that atipamezole would be an effective therapy in male impotence in humans as  
30 well.

Another  $\alpha_2$ -adrenoreceptor antagonist, yohimbine, is currently used for  
the treatment of male impotence. Yohimbine increases noradrenergic

neurotransmission and has been reported to facilitate the sexual capacity of male animals, although the results of different studies are conflicting. Atipamezole is, however clearly advantageous over yohimbine for this use because of its excellent selectivity. The  $\alpha_2/\alpha_1$  selectivity ratio of atipamezole is

5 200-300 times higher than that of yohimbine.

### Experimental

Three male and one female stump-tail macaques (*Macaca Arctoides*) were studied in the experiments. The ages of the males were 13, 16 and about  
10 24 years. The age of the female was 6 years.

During the testing period the couple being tested was housed in a single cage (0.6 x 0.9 x 1.2 m) with two compartments. Between the sessions and during the first 10 min of each session a sliding wall separated the male and the female in the test cage. The sliding wall was made of iron bars. The monkeys  
15 could see and touch each other through the sliding wall. After the i.m. administration of the studied drug dose/saline control to the male, the observation of the sexual behaviour began as described below. Ten minutes after the drug administration the sliding wall between the male and the female was pulled away, and the observation of sexual activity continued for the next  
20 20 min. At the end of the observation period (=30 min after the drug administration) the sliding wall was replaced. Every time a new couple was being tested, the first three sessions were done as above but without the drug administrations to allow habituation of the couple to each other. These first three sessions were not included in the results.

25 The time of occurrence and duration of the following behaviour was observed: perineal investigation, mounting, ejaculation, tying, grooming, direct aggression towards the female, yawns, self-scratching, teeth grinding, shaking of cage and masturbation. In the current report only the number of ejaculations in each session is given, since it gave the most straight forward index of male  
30 sexual behaviour. For the same reason, the ejaculations obtained by masturbation and intercourse were pooled in the results.

The experiments were performed once daily seven days a week. Atipamezole was given every other day and saline control during other days. The preliminary results in one monkey indicated that there was no difference in  
35 the effect of atipamezole whether it was given every third or other day.

Atipamezole doses varied from 0.01 to 0.3 mg/kg (dissolved in saline to get a volume of about 0.2 ml). Each dose was tested 5-15 times in each monkey. Taking into account the saline days, the testing of one dose in one monkey took from 10 days to one month. The order of testing each dose was varied between the monkeys to counterbalance possible serial effects. The difference in the number of ejaculations obtained at a given atipamezole dose and the corresponding saline control days was used as an index of the effect of atipamezole on sexual behaviour. This is how the possible variation in the baseline sexual activity (represented by ejaculations during saline days) could be minimized. The incidence of ejaculations (the percentage of saline days with one or more ejaculations) during saline days was used as an index of baseline sexual activity of each male. One way analysis of variance (ANOVA) and Student's t-test were used in statistical evaluation of the data.  $P < 0.05$  was considered to represent a significant difference.

In the saline (=control) conditions the incidences of sexual activity (percentage of sessions with ejaculations produced by copulation and/or masturbation) in the three male monkeys were 7%, 12% and 26%. The oldest male had the lowest and the youngest male the highest incidence of sexual activity in control (=saline) conditions. The sexual activity of the males in saline or atipamezole conditions was not dependent on the estrous cycle of the female.

The results obtained with atipamezole are shown in Figure 1 A -D.


Atipamezole increased the number of ejaculations in a dose-dependent way in all three male monkeys (for each individual;  $p < 0.05$ , ANOVA; Figure 1 A-C). The lowest effective dose of atipamezole varied from 0.01 to 0.08 mg/kg depending on the individual; the younger the male, the lower the lowest effective dose. The average atipamezole-induced increase of ejaculations over the three males also was dose-dependent and significant ( $p < 0.05$ , ANOVA; Figure 1 D). No other behavioral effects produced by atipamezole were observed except increased alertness.

The drug is preferably administrated perorally, transmucosally, intravenously, intramuscularly or transdermally. The preferable daily dose range is about 0.01 to 1 mg/kg, preferably 0.05 to 0.3 mg/kg for i.v., i.m., transmucosal or transdermal administration and 0.3 to 10 mg/kg for peroral administration.

**CLAIMS**

1. Use of atipamezole or a pharmaceutically acceptable acid addition salt thereof for the treatment of male sexual impotence.  
5
2. Use of atipamezole or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment of male sexual impotence.  
10
3. Pharmaceutical composition comprising atipamezole or a pharmaceutically acceptable acid addition salt thereof for the treatment of male sexual impotence.
- 15 4. A method of treatment of male sexual impotence comprising administration of an effective amount of atipamezole or a pharmaceutically acceptable acid addition salt thereof.

FIGURE 1



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/FI 92/00191

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5                      A 61 K 31/415		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	Drugs Future, vol. 15, no. 5, 1990, "Atipamezole", pages 448-452, see page 449 ---	1-4
X	Annals of Clinical Research, vol. 20, 1988; E. MacDONALD et al.: "Therapeutic applications of drugs acting on alpha-adrenoceptors", pages 298-310, see abstract; pages 300,302 ---	1-4
P,X	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 42, 1992, Pergamon Press Ltd, (US), I. LINNANKOSKI et al.: "Increased sexual behavior in male Macaca arctoides monkeys produced by atipamezole, a selective alpha2-adrenoceptor antagonist", pages 197-200, see whole document -----	1-4
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
21-08-1992		02. 11. 92
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		